GENFIT CORP.
245 First Street - 18th Floor
Suite 1806
Cambridge
Massachusetts
02142
United States
Tel: 617-444-8416
Fax: 617- 444-8405
Website: http://www.genfit.com/
Email: Karen.Miller@Genfit.com
About GENFIT CORP.
Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.
Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.
Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.
GENFIT
Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
59120 Loos
France
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001
151 articles with GENFIT CORP.
-
GenFit’s lead product candidate elafibranor snagged Breakthrough Therapy Designation from the U.S. Food and Drug Administration as a treatment for Primary Biliary Cholangitis (PBC) following strong Phase II results that demonstrated the safety and efficacy of the medication.
-
GENFIT announces FDA Grant of Breakthrough Therapy Designation to Elafibranor for the Treatment of PBC
4/18/2019
FDA grants elafibranor Breakthrough Therapy Designation, based on Phase 2 data, for treatment of PBC (Primary Biliary Cholangitis) in adults with inadequate response to UDCA
-
GENFIT to Present Additional Data from the Positive Phase 2 Clinical Trial Evaluating Elafibranor in Primary Biliary Cholangitis at the International Liver Congress™ 2019
4/13/2019
New data also suggest an improvement in pruritus – a major symptom of PBC – with a median change in VAS of -24% (80mg) and -49% (120mg) vs. -7% (placebo)
-
GENFIT announces Upcoming Presentations on NASH, PBC and Diagnostics at the European Association for the Study of the Liver (EASL) International Liver Congress 2019
4/4/2019
Elafibranor Phase 2 data in PBC accepted for late-breaker oral presentation
-
Genfit, with offices in Lille, France and Cambridge, Mass., launched its initial public offering (IPO) on the Nasdaq on March 27. Dean Hum, chief operating officer of Genfit, took time out to speak with BioSpace about the company, the IPO and elafibranor.
-
A summary of IPOs from companies in the biotech and pharma world since March 1, 2019.
-
GENFIT Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market
3/27/2019
GENFIT is a French biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases
-
March has been a busy month for biopharma and medical device company initial public offerings. Here’s a look at the top IPO stories for the month.
-
France-based GenFit launched its $132 million initial public offering plans in order to raise funds that will be used to support the Phase III trial and planned commercialization of its elafibranor compound for non-alcoholic steatohepatitis (NASH).
-
GENFIT announces Launch of Proposed Global Offering and Nasdaq listing
3/14/2019
GENFIT S.A. announced its intention to issue and sell, subject to market and other conditions, 5,000,000 of its ordinary shares in a global offering to specified categories of investors, comprised of an initial public offering of American Depositary Shares, each representing one ordinary share, in the United States, and a concurrent private placement of ordinary shares in Europe and other countries outside of the US.
-
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
-
GENFIT announces FDA Protocol Clearance for Phase 2 Clinical Trial of Elafibranor in Pediatric NASH
3/11/2019
FDA accepts study protocol, providing green light for GENFIT to initiate Phase 2 clinical trial in pediatric NASH
-
GENFIT files Registration Statement for Proposed Initial Public Offering in the United States
2/28/2019
GENFIT announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its American Depositary Shares, each representing one ordinary share, in the United States, and a concurrent private placement of its ordinary shares in Europe and other countries outside of the United States and Canada.
-
A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
-
Loos, France-based Genfit announced it is planning an initial public offering (IPO) to raise $100 million. Genfit is a late-stage biopharma company focused on developing therapeutics for metabolic and liver diseases. The area that has the most interest is nonalcoholic steatohepatitis, or NASH.
-
GENFIT: Publication of the 2018 Registration Document
2/27/2019
GENFIT, a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, announces the filing of its 2018 Registration Document with the Autorité des marchés financiers.
-
GENFIT: Reports Full-Year 2018 Financial Results: cash position of €207.2m as of 12.31.2018
2/4/2019
Cash position of €207.2 million as of December 31, 2018, compared to €273.8 million as of December 31, 2017
-
Nonalcoholic steatohepatitis (NASH) is prevalent in the U.S. and developing countries, but under that name, is largely unknown to the general public. NASH is a liver disease similar to cirrhosis, but which occurs in people who drink little or no alcohol.
-
GENFIT announces its Financial Calendar for 2019
1/21/2019
GENFIT today announces its provisional financial calendar for 2019
-
GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)
1/3/2019
Multi-Biomarker Test Will Provide the Clinical Research Community with a Non-Invasive Tool to Identify and Monitor Patients with NASH and Significant Fibrosis